PAGE-1 Activators
PAGE-1 activators represent a specialized category of compounds designed to modulate the function of the PAGE-1 protein, which stands for P Antigen Family Member 1, part of the GAGE/PAGE family of proteins. Activators of PAGE-1 would therefore be molecules that can enhance its activity or expression levels. The mechanism by which these activators function could involve direct interaction with PAGE-1, affecting its stability, localization, or altering its interaction with other cellular components. These activators might also work by influencing the cellular pathways that control the expression of PAGE-1 or by modifying the epigenetic state of the PAGE-1 gene, leading to upregulation of its protein levels.
The exploration and development of PAGE-1 activators would require a sophisticated understanding of the protein's structure and regulatory mechanisms. To this end, advanced research techniques such as next-generation sequencing or chromatin immunoprecipitation could be used to study the gene regulation of PAGE-1, while mass spectrometry might be employed to investigate post-translational modifications that affect its function. With this information, a targeted approach could be taken to design molecules that can interact with PAGE-1 or its regulatory elements. High-throughput screening assays would be developed to identify small molecules or peptides that have the ability to increase PAGE-1 activity. These assays would likely be based on reporter systems in which the activation of PAGE-1 leads to a quantifiable signal, enabling rapid screening of large chemical libraries.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin raises intracellular levels of cAMP, which in turn activates PKA. PKA phosphorylates various substrates that can lead to the enhancement of PAGE-1 activity by influencing its related signaling processes. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin functions as a calcium ionophore, increasing intracellular calcium concentration. Elevated calcium can activate calcium-dependent protein kinases, which may enhance PAGE-1 activity through phosphorylation events. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which phosphorylates a plethora of proteins. PKC activation can lead to the enhancement of PAGE-1 activity via PKC-mediated signaling pathways. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
As a cAMP analog, 8-Bromo-cAMP activates cAMP-dependent pathways, including PKA. Activation of these pathways can enhance PAGE-1 activity through secondary messenger systems. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
This lipid signaling molecule activates sphingosine-1-phosphate receptors, which can lead to the activation of downstream kinases and phosphatases, potentially enhancing PAGE-1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can lead to alterations in downstream signaling pathways that may result in the enhanced activity of PAGE-1 through compensatory mechanisms. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as an ionophore for Ca2+ and Mg2+, increasing intracellular calcium levels. This rise in calcium can activate signaling pathways that enhance PAGE-1 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor with a broad spectrum of targets. By inhibiting certain kinases, it can lead to enhanced PAGE-1 activity indirectly through altered signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK can lead to an increase in PAGE-1 activity through the alteration of related signaling pathways. | ||||||
Calcium dibutyryladenosine cyclophosphate | 362-74-3 | sc-482205 | 25 mg | $147.00 | ||
Dibutyryl-cAMP, a cAMP analog, activates the cAMP-dependent PKA. This activation can lead to the enhancement of PAGE-1 activity as PKA phosphorylates targets involved in PAGE-1's signaling pathways. | ||||||